Apellis Pharmace Form 4 Filings

Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported multiple equity changes tied to the company’s acquisition by Biogen. On May 14, 2026, he tendered 65,955 shares of common stock in a tender offer, receiving $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 per share upon specified milestones.

In connection with the same merger, his outstanding stock options and restricted stock unit (RSU) awards were either cancelled for no value if deeply out of the money, or converted into rights to cash payments based on the $41.00 cash amount and corresponding CVRs. The filing shows several compensation-related grants of common stock and RSU‑linked awards on the same date and paired dispositions back to the issuer under the merger terms. After these transactions, Chopas holds no remaining direct common stock or stock options in Apellis, which is now a wholly owned subsidiary of Biogen.

Apellis Pharmaceuticals director Mikael Dolsten reported dispositions tied to the company’s acquisition by Biogen. He disposed of 14,312 shares of common stock and 24,135 stock options in connection with a tender offer and subsequent merger. Each common share was exchanged for $41.00 in cash plus one contingent value right (CVR), with potential additional cash payments of up to $4.00 per share if specified milestones are achieved. Vested options with exercise prices below $41.00 were cancelled and converted into cash equal to $41.00 minus the exercise price per option share, plus one CVR per underlying share. Following these transactions, Dolsten reported no remaining direct holdings or options in Apellis.

Apellis Pharmaceuticals chief research and development officer Leslie Meltzer reported equity transactions tied to the closing of the company’s merger with Biogen. Common shares tendered before the offer expiration were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash per share upon specified milestones. The filing shows 107,024 shares of common stock disposed of pursuant to the tender offer and 92,592 stock options with a $27.93 exercise price cancelled in exchange for cash and CVRs. Restricted stock units were converted into rights to future cash and CVR payments that continue to vest over time, including performance-based awards certified at 200% of target after relative total shareholder return reached the 93.3rd percentile. Following these transactions, the report shows no remaining common stock or options held directly.

Apellis Pharmaceuticals director Paul R. Fonteyne reported disposing of his equity interests in connection with Biogen’s acquisition of Apellis. On the Form 4 date, multiple blocks of Apellis common stock were either surrendered to the issuer or delivered into a tender offer.

Under the merger agreement among Apellis, Biogen and a Biogen subsidiary, each tendered share of Apellis common stock was exchanged for $41.00 in cash per share plus one contractual, non-transferable contingent value right, or CVR, per share. Each CVR can pay up to an additional $4.00 in cash if specified milestones are met.

In addition, vested or transaction-vested stock options with exercise prices below $41.00 were cancelled and converted into cash payments equal to the spread over $41.00, plus one CVR per underlying share, while higher-priced options at or above $45.00 per share were cancelled without consideration. Following these transactions, the positions reported in this Form 4 show zero shares remaining.

Apellis Pharmaceuticals’ Chief Financial Officer Timothy Sullivan reported multiple equity award changes tied to the company’s acquisition by Biogen. Common shares tendered before the offer’s expiration were exchanged for $41.00 in cash per share plus one contractual contingent value right (CVR) per share.

Each CVR can pay up to an aggregate $4.00 in cash if specified milestones are achieved. After completion of the tender offer, Biogen’s subsidiary merged into Apellis, making Apellis a wholly owned subsidiary. Outstanding common stock was automatically converted into the right to receive the cash-and-CVR offer price.

Restricted stock units were cancelled and converted into cash-and-CVR rights that continue to vest over time, with performance conditions removed. Vested and certain unvested stock options were cancelled and converted into cash and/or CVRs depending on exercise price, while options with exercise prices at or above $45.00 were cancelled without consideration.

Apellis Pharmaceuticals director Alec Machiels reported multiple disposals of Apellis common stock tied to Biogen’s acquisition of the company. On May 14, 2026, shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones. Dispositions included 384,989 directly held shares and indirect holdings such as 250,000 shares held by Bauhaus 1 LLC and 150,000 shares in a spouse trust. Following these actions and the cancellation of various stock options, the filing shows Machiels with no remaining Apellis equity, as Apellis became a wholly owned subsidiary of Biogen.

Apellis Pharmaceuticals’ Chief Scientific Officer Pascal Deschatelets reported multiple equity transactions tied to the closing of Biogen’s acquisition of the company. On the completion of Biogen’s tender offer and merger, 1,177,222 common shares were disposed of into the offer.

Each tendered share was exchanged for $41.00 in cash plus one contingent value right (CVR) with potential additional cash payments of up to an aggregate $4.00 per share upon specified milestones. Outstanding RSUs and stock options were cancelled or converted into cash-and-CVR rights based on their vesting terms and exercise prices, while certain underwater options were cancelled without consideration.

Apellis Pharmaceuticals director Gerald Chan reported disposing of his holdings in connection with the company’s sale to Biogen. On May 14, 2026, he disposed of multiple blocks of Apellis common stock, including 25,666 shares classified as a tender-offer disposition, leaving zero shares reported as directly owned.

The filing explains that Apellis agreed to be acquired by Biogen through a tender offer and merger. Each Apellis share tendered before the offer expired was exchanged for $41.00 in cash per share plus one contingent value right, or CVR. Each CVR can pay up to an aggregate of $4.00 in cash if specified milestones are achieved. Vested stock options with exercise prices below $41.00 were cancelled and converted into cash equal to the spread plus one CVR per underlying share, while options with exercise prices at or above $45.00 were cancelled without payment.

Apellis Pharmaceuticals’ chief technical officer Nur Nicholson reported multiple equity award changes tied to the company’s acquisition by Biogen. Common shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones. Restricted stock units (RSUs) were cancelled and replaced with rights to receive cash based on the offer price and one CVR per underlying share, continuing to vest over time but without performance conditions. Stock options were cancelled and, depending on their exercise price, converted into cash plus CVRs, CVRs only, or, for options with exercise prices at or above $45.00, cancelled without consideration.

Apellis Pharmaceuticals director Keli Walbert reported a series of dispositions tied to the company’s acquisition by Biogen. Under the merger agreement, Apellis shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash, subject to milestones and tax withholding. On the merger’s effective date, Walbert disposed of common stock both back to the issuer and pursuant to the tender offer, and all reported stock options with exercise prices below $41.00 were cancelled in exchange for cash based on the spread to the cash amount plus CVRs. Following these transactions, the filing shows no remaining directly held Apellis common shares or stock options for this reporting person.

Apellis Pharmaceuticals executive Mark Jeffrey DeLong reported multiple equity award changes tied to the company’s merger with Biogen. Common shares tendered before the merger were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones.

Following completion of the tender offer, Biogen’s subsidiary merged into Apellis, making Apellis a wholly owned subsidiary. In connection with this, DeLong disposed of common stock and stock options back to the issuer or via the tender offer, and received new stock awards, including grants of 18,303, 36,606, 19,006 and 41,250 shares of common stock as compensation-related awards rather than open‑market purchases.

Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported multiple share and option dispositions tied to the closing of Biogen’s acquisition of Apellis. On May 14, 2026, Apellis became a wholly owned subsidiary of Biogen after a tender offer and follow-on merger.

According to the merger terms, each tendered share of Apellis common stock was exchanged for $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 in cash upon specified milestones. The Form 4 shows blocks of common shares, including some held indirectly through O'Brien’s spouse, disposed of in the tender offer and related issuer transactions.

Vested stock options with exercise prices below $41.00 were cancelled and converted into cash equal to the spread between the offer price and the exercise price, plus one CVR per underlying share. Options with exercise prices at or above $45.00 were cancelled without payment. After these transactions, the filing shows no remaining reported common stock or options for O'Brien.

Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher reported multiple equity transactions tied to the completion of Apellis’s merger with a Biogen subsidiary. Common shares tendered before the offer expired were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash per share if specified milestones are met. Following the tender offer and subsequent merger effective at the filing of the certificate of merger on May 14, 2026, Apellis became a wholly owned subsidiary of Biogen. In connection with the merger, previously outstanding restricted stock units and vested stock options were cancelled and converted into rights to receive cash based on the $41.00 cash amount plus one CVR per underlying share, with vesting and “double-trigger” conditions generally preserved but with performance-based vesting removed. Boucher also received new awards of 30,146 and 15,073 shares of common stock as compensation grants, which she now holds directly, and all listed stock options were disposed of to the issuer.

Apellis Pharmaceuticals director Craig A. Wheeler exited his Apellis stake as part of the company’s merger with Biogen. On May 14, 2026, he disposed of common shares and cancelled vested stock options in transactions classified as dispositions to the issuer and tender-offer dispositions.

Under the merger terms, each Apellis common share was exchanged for $41.00 in cash plus one contingent value right, which may pay up to an additional $4.00 per share if specified milestones are met. Vested in-the-money options were cancelled for cash based on the excess of the cash amount over the exercise price, plus one contingent value right per underlying share. Following these transactions, Wheeler reported no remaining Apellis common stock or stock options.

Apellis Pharmaceuticals’ General Counsel, David O. Watson, reported multiple stock and option transactions tied to the company’s acquisition by Biogen. Common shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 in cash if milestones are met. Several restricted stock unit awards were converted into the right to receive cash based on this cash amount and associated CVRs, with vesting tied to continued service. Vested stock options with lower exercise prices were cashed out for cash and CVRs, while higher‑priced options at or above $45.00 per share were cancelled without consideration. These actions are mechanical effects of the merger agreement rather than open‑market trading decisions.

Apellis Pharmaceuticals’ chief executive Cedric Francois reported major equity changes tied to the company’s merger with Biogen. Common shares tendered in the offer were exchanged for $41.00 per share in cash plus one contingent value right, which can pay up to an additional $4.00 in cash upon specified milestones. The filing shows large dispositions of common stock and stock options, both directly and through several family trusts, in connection with the tender offer and subsequent merger. Equity awards such as options and restricted stock units were cancelled and converted into rights to receive cash and CVRs, or, for higher‑strike options, were cancelled without consideration, reflecting standard change‑of‑control treatment for executive equity.

Apellis Pharmaceuticals’ Chief Medical Officer Caroline Baumal reported multiple equity changes tied to the closing of Biogen’s acquisition of Apellis. On May 14, 2026, her common shares were disposed of to the issuer and through the tender offer, and she received new stock awards as part of the transaction.

Under the merger terms, tendered Apellis common stock was exchanged for $41.00 in cash per share plus one contingent value right (CVR) of up to $4.00 per share, subject to specified milestones. Restricted stock units and in-the-money options were either converted into cash-and-CVR rights or cancelled, leaving Baumal with no remaining stock options reported after the transaction but new time-based stock awards.

Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a bona fide gift of 900 shares of common stock. The shares were transferred at no price as a charitable contribution. After this gift, she directly holds 86,525 shares, indicating she retains a substantial equity stake in the company.

Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported two bona fide gift transfers of common stock. On April 17, 2026, he gifted a total of 22,192 shares, including 11,096 shares transferred to The Timothy E Sullivan Irrevocable Trust of 2023.

After these gifts, the filing shows 71,492 shares held indirectly through the irrevocable trust and 140,945 shares held directly. The footnote states he disclaims beneficial ownership of shares held by the trust except to the extent of his pecuniary interest.

Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported an internal share restructuring involving her spouse's holdings. A total of 5,750 shares of Common Stock were distributed from a trust to an account held directly by her spouse, and her beneficial ownership is unchanged. Following this, she reports 25,666 shares held directly and 5,750 shares held indirectly through her spouse.

Apellis Pharmaceuticals Chief Executive Officer Cedric Francois reported gift transfers of common stock. On March 11, 2026, entities associated with him made bona fide gifts totaling 129,738 shares, including a transfer of 64,869 shares to The Cedric Francois Irrevocable Trust of 2023 - 2.

After these gifts, he directly holds 425,968 shares. The filing also lists indirect holdings through several trusts, including 372,815 shares in The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares in The Cedric Francois Irrevocable Trust of 2023, 300,000 shares in The Francois Grossi Trust, and 234,411 shares in The Francois-DuBois Educational Trust.

Apellis Pharmaceuticals director Mikael Dolsten reported receiving new equity awards. On February 27, 2026, he was granted stock options for 24,135 shares at an exercise price of $20.96 per share, vesting in equal one-third installments annually over three years, subject to continued service.

He also received 14,312 shares of common stock as a restricted stock unit grant. This restricted stock unit will fully vest on the first anniversary of the grant date, or upon a later termination of his service as a director at his election, provided he continues serving as a director.

Apellis Pharmaceuticals Chief Business & Strat Officer Mark DeLong reported a small stock sale mainly for tax purposes. On February 11, 2026, he sold 368 shares of Apellis common stock at $22.1537 per share to cover tax withholding tied to Restricted Stock Units released on February 10, 2026. After this transaction, he directly owned 114,591 shares of Apellis common stock.

Apellis Pharmaceuticals Chief Executive Officer Cedric Francois reported an option exercise and related share acquisition. On 02/03/2026, a fully vested stock option for 8,840 shares of common stock was exercised at $3.76 per share, increasing his directly held common stock to 490,837 shares.

The filing also lists additional common stock positions held indirectly through several trusts, including The Cedric Francois Irrevocable Trust of 2023, The Cedric Francois Irrevocable Trust of 2023 - 2, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where he disclaims beneficial ownership except to the extent of any pecuniary interest.

Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher received an equity grant of 30,146 shares of common stock in the form of restricted stock units on January 28, 2026. The award vests 25% each year over four years, subject to continued service.

Following this grant, Boucher beneficially owns 127,804 shares of Apellis common stock in direct ownership. This filing reflects routine equity-based compensation rather than an open-market purchase or sale.

Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported an equity grant of 16,150 shares of common stock on January 28, 2026. The Form 4 shows the transaction coded as an acquisition at a price of $0 per share, tied to a restricted stock unit award.

According to the footnote, this award consists of restricted stock units that vest 25% each year over four years from the grant date, contingent on continued service. Following this grant, Chopas is shown as directly beneficially owning 65,955 shares of Apellis common stock.

Apellis Pharmaceuticals’ Chief Business & Strat Officer Mark DeLong received an award of 36,606 shares of common stock on January 28, 2026 as a restricted stock unit grant. These RSUs vest 25% each year over four years, contingent on continued service. Following this grant, DeLong directly beneficially owns 114,959 shares of Apellis common stock.

Apellis Pharmaceuticals Chief Scientific Officer receives new equity grant. Pascal Deschatelets was awarded 25,840 shares of Apellis common stock on January 28, 2026 as a restricted stock unit grant at a price of $0 per share. These units vest 25% each year over four years, conditioned on continued service. Following this award, he beneficially owns 1,177,222 shares of Apellis common stock held directly.

Apellis Pharmaceuticals’ Chief Research and Development officer Leslie Meltzer reported a stock-based compensation grant. On January 28, 2026, Meltzer received 45,220 shares of Apellis common stock at a price of $0 per share, reflecting a restricted stock unit award.

Following this grant, Meltzer beneficially owns 107,024 shares directly. The award vests 25% each year over four years from the grant date, and vesting is conditioned on continued service with the company.

Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026. The shares were awarded at a price of $0 per share as part of an equity compensation program.

According to the footnote, this award is in the form of restricted stock units that vest 25% each year over four years from the grant date, subject to continued service. Following this grant, Nicholson beneficially owns 116,338 shares of Apellis common stock in direct ownership.

Apellis Pharmaceuticals’ chief financial officer, Timothy E. Sullivan, reported receiving an award of 58,140 shares of common stock on January 28, 2026 at a price of $0 per share, representing a restricted stock unit grant that vests 25% annually over four years, subject to continued service.

Following the award, he reports 152,041 shares of Apellis common stock held directly. An additional 60,396 shares are reported as indirectly held through The Timothy E Sullivan Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Apellis Pharmaceuticals reported that its General Counsel, David O. Watson, received a grant of 55,986 shares of common stock on January 28, 2026, at a price of $0, described as a restricted stock unit award vesting 25% annually over four years, subject to continued service. Following this award, he directly beneficially owns 144,517 shares of common stock. He also reports indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest.

Apellis Pharmaceuticals CEO Cedric Francois reported a new equity grant of 195,952 shares of common stock on January 28, 2026, awarded as restricted stock units at $0 per share. Following this grant, he directly holds 481,997 Apellis common shares.

The RSU award vests 25% each year over four years from the grant date, subject to continued service. Additional Apellis shares are held by several trusts, including The Cedric Francois Irrevocable Trust of 2023 - 2, The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where Francois disclaims beneficial ownership except for any pecuniary interest.

Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine insider transaction involving company common stock. On January 22, 2026, she sold 2,797 shares of Apellis common stock at a price of $21.7654 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations arising from restricted stock units that were released on January 21, 2026.

After this sale, Baumal beneficially owned 86,527 Apellis shares, all held directly. The filing characterizes this as a tax-related sale rather than a discretionary open-market reduction in her overall ownership.

Apellis Pharmaceuticals insider activity: VP and Chief Accounting Officer James George Chopas reported a sale of Apellis Pharmaceuticals common stock mainly for tax purposes. On January 22, 2026, he sold 2,064 shares of common stock at a price of $21.7654 per share. According to the footnote, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he continued to beneficially own 49,805 shares of Apellis common stock directly.

Apellis Pharmaceuticals reported an insider stock transaction by Chief Business & Strategy Officer Mark DeLong. On January 22, 2026, he sold 3,371 shares of Apellis common stock at $21.7654 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to restricted stock units that were released on January 21, 2026, meaning the sale was tied to equity compensation rather than an open-market liquidation of a larger position. After this sale, DeLong beneficially owned 78,353 shares of Apellis common stock.

Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a sale of Apellis common stock in a Form 4 filing. On January 22, 2026, he sold 5,928 shares of common stock at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations on restricted stock units that were released on January 21, 2026. After this transaction, Deschatelets directly beneficially owned 1,151,382 shares of Apellis common stock.

Apellis Pharmaceuticals, Inc. insider activity: Chief Executive Officer and director Cedric Francois reported selling 27,192 shares of Apellis common stock on January 22, 2026 at a price of $21.7654 per share. The filing explains that this sale was made to cover tax withholding on restricted stock units that were released on January 21, 2026. After this transaction, Francois directly held 286,045 Apellis shares.

In addition to his direct holdings, the filing lists indirect holdings in several trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. These shares are held by the respective trusts, and Francois disclaims beneficial ownership except to the extent of any pecuniary interest.

Apellis Pharmaceuticals chief technical officer files insider share sale

Apellis Pharmaceuticals chief technical officer Nur Nicholson reported selling 7,725 shares of Apellis common stock on January 22, 2026 at a price of $21.7654 per share. According to the filing, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 21, 2026. After this transaction, Nicholson beneficially owned 71,118 shares of Apellis common stock held directly.

Apellis Pharmaceuticals, Inc. Chief Financial Officer Timothy Eugene Sullivan reported a sale of 10,287 shares of common stock on January 22, 2026. The shares were sold at a price of $21.7654 per share and the filing explains that this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026.

After this tax‑related sale, Sullivan directly beneficially owned 93,901 shares of Apellis common stock. In addition, 60,396 shares are held indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. The filing notes that the securities in the trust are held by that trust with Patrick O. Collins as trustee, and Sullivan disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest in them.

Apellis Pharmaceuticals General Counsel David O. Watson reported a sale of company common stock in an insider filing. On January 22, 2026, he sold 7,832 shares of Apellis common stock at $21.7654 per share, and the filing explains this sale was made to cover tax withholding on Restricted Stock Units that were released on January 21, 2026. After this transaction, he directly holds 88,531 common shares.

The filing also lists indirect holdings. A custodial account held by him for the sole benefit of his minor children holds 10,000 common shares50,136 common shares are held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Watson Education Trust is shown with 0 shares, and he likewise disclaims beneficial ownership in that trust except for any pecuniary interest.

Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine share sale related to tax withholding. On January 20, 2026, she sold 1,882 shares of Apellis common stock at a price of $19.7929 per share. According to the footnote, this sale was made to cover tax withholding on Restricted Stock Units that were released on January 16, 2026.

After this transaction, Baumal beneficially owned 89,324 shares of Apellis common stock in direct ownership form. The filing indicates this was a single non-derivative transaction coded as a sale, tied specifically to the vesting of equity compensation rather than an open-market discretionary sale.

Apellis Pharmaceuticals VP/Chief Accounting Officer James George Chopas reported a small sale of company stock in connection with equity compensation. On January 20, 2026, he sold 726 shares of Apellis common stock at a price of $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.

After this transaction, Chopas beneficially owned 51,869 shares of Apellis common stock in direct ownership. The filing indicates the transaction was a routine tax-related sale rather than an open-market discretionary reduction of his overall stake.

Apellis Pharmaceuticals Chief Business & Strat Officer Mark Jeffrey DeLong reported a small stock sale related to tax withholding. On January 20, 2026, he sold 1,334 shares of Apellis common stock at an average price of $19.7929 per share, coded as a sale transaction.

According to the filing, this sale represents shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, DeLong directly owns 81,724 shares of Apellis common stock.

Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a small share sale related to tax withholding. On January 20, 2026, he sold 909 shares of Apellis common stock at an average price of $19.7929 per share. The filing explains that these shares were sold to cover taxes due on Restricted Stock Units that vested on January 16, 2026.

After this transaction, Deschatelets beneficially owned 1,157,310 shares of Apellis common stock in direct form. The transaction is reported on a Form 4 as a non-derivative disposition coded "S," indicating an open-market or similar sale.

Apellis Pharmaceuticals, Inc. Chief Executive Officer and director Cedric Francois reported a sale of common stock mainly tied to taxes on equity compensation. On January 20, 2026, he sold 8,182 shares of Apellis common stock at $19.7929 per share, in a transaction described as covering tax withholding on restricted stock units that were released on January 16, 2026. Following this sale, he directly owned 313,237 shares of common stock.

In addition to his direct holdings, the filing lists several indirect holdings through trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. The filing states that Francois disclaims beneficial ownership of shares held in these trusts except to the extent of his pecuniary interest.

Apellis Pharmaceuticals, Inc. insider transaction: Chief Technical Officer Nicholson Nur reported a sale of 2,203 shares of Apellis common stock on January 20, 2026, at a price of $19.7929 per share. According to the footnote, these shares were sold to cover tax withholding related to Restricted Stock Units that were released on January 16, 2026, rather than as an open-market discretionary sale. After this transaction, Nur beneficially owned 78,843 shares of Apellis common stock in direct ownership.

Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported a small sale of company stock primarily to cover taxes from equity compensation. On January 20, 2026, he sold 2,892 shares of common stock at an average price of $19.7929 per share, described as shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, he directly held 104,188 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023, for which a separate trustee, Patrick O. Collins, acts, and over which Sullivan disclaims beneficial ownership except to the extent of his pecuniary interest.

Apellis Pharmaceuticals’ general counsel, David O. Watson, reported selling 2,475 shares of common stock on January 20, 2026 at $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.

After this transaction, Watson beneficially owned 96,363 common shares directly. He also reported indirect holdings, including 10,000 shares in a custodial account for the sole benefit of his minor children, and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest. The Watson Education Trust reported holding no shares following the reported transactions, with similar beneficial ownership disclaimers.